MedElevator
Войти в исследования European journal of clinical pharmacology · 2026
Safety and efficacy of DOACs for non-cirrhotic splanchnic vein thrombosis: a single centre retrospective analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Depietri Luca, Fabbri Filippo B, Veropalumbo Maria Rosaria, Spaggiari Eleonora, Corradini Sara, Leone Maria Cristina, Casali Annamaria, Iotti Matteo
Аннотация
BACKGROUND: In recent years, increasing evidence has emerged regarding the use of direct oral anticoagulants (DOACs) for the treatment of splanchnic vein thrombosis (SVT) in non-cirrhotic patients. However, available data are predominantly retrospective, derived from small and heterogeneous cohorts; consequently, the use of DOACs for this indication remains off-label.
METHODS: To further evaluate the safety and efficacy of DOACs in this setting, 21 consecutive patients with acute non-cirrhotic SVT were enrolled and treated with DOACs for a minimum of 6 months.
RESULTS: No cases of SVT progression, recurrence, or major bleeding were observed during follow-up. One patient experienced a minor bleeding event.
CONCLUSIONS: These findings are consistent with previous reports indicating a favorable safety profile of DOACs, with a low risk of bleeding. However, conclusions regarding efficacy remain uncertain, precluding definitive inferences on their effectiveness in non-cirrhotic SVT. Larger, well-designed prospective studies are required to clarify the true efficacy of DOACs in this clinical setting.
METHODS: To further evaluate the safety and efficacy of DOACs in this setting, 21 consecutive patients with acute non-cirrhotic SVT were enrolled and treated with DOACs for a minimum of 6 months.
RESULTS: No cases of SVT progression, recurrence, or major bleeding were observed during follow-up. One patient experienced a minor bleeding event.
CONCLUSIONS: These findings are consistent with previous reports indicating a favorable safety profile of DOACs, with a low risk of bleeding. However, conclusions regarding efficacy remain uncertain, precluding definitive inferences on their effectiveness in non-cirrhotic SVT. Larger, well-designed prospective studies are required to clarify the true efficacy of DOACs in this clinical setting.